Skip to content
Exosome consulting
  • Home
  • About us
  • ServicesExpand
    • For indusry
    • For academia
    • For investors
  • News
  • Career
  • Contact
Exosome consulting
  • FDA Modernization Act 2.0 and development of exosome-based therapies
    White paper

    FDA Modernization Act 2.0 and development of exosome-based therapies

    Posted onJanuary 4, 2023September 12, 2024

    Read our analysis on how changes to the Section 505 of the Federal Food, Drug, and Cosmetic Act introduced by the FDA Modernization…

    Listen to the Message FDA Modernization Act 2.0 and development of exosome-based therapiesContinue

  • Introducing KnowlEx™ Cloud
    White paper

    Introducing KnowlEx™ Cloud

    Posted onJanuary 1, 2023September 12, 2024

    Are you ready to take a peek behind the curtain of Exosome Consulting and see how we help our clients make the right…

    Listen to the Message Introducing KnowlEx™ CloudContinue

  • Exosome-based diagnostics and therapeutics markets
    White paper

    Exosome-based diagnostics and therapeutics markets

    Posted onDecember 26, 2022September 12, 2024

    Our new INSIGHTS paper, “Investing into extracellular vesicle-based diagnostic and therapeutics. Uncovering the opportunities, challenges, and restraints in the emerging markets.” is live….

    Listen to the Message Exosome-based diagnostics and therapeutics marketsContinue

  • ESG
    White paper

    ESG and exosome-focused companies

    Posted onDecember 16, 2022September 12, 2024

    The end of the era of cheap money, characterized by low-interest rates and easy access to credit, has significant implications for businesses seeking…

    Listen to the Message ESG and exosome-focused companiesContinue

Contact

Exosome Consulting UG (haftungsbeschränkt)
Henkestraße 91,
91052 Erlangen
Germany.

[email protected]

Impressum © 2025 Exosome consulting

  • Home
  • About us
  • Services
    • For indusry
    • For academia
    • For investors
  • News
  • Career
  • Contact